Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026?

The article compares two biotech companies with contrasting profiles: Kyverna Therapeutics, a clinical-stage firm developing cell therapies for autoimmune diseases with no approved products and significant losses, versus Vertex Pharmaceuticals, an established leader generating $12 billion in revenue with a dominant cystic fibrosis franchise. The author recommends Vertex as the better 2026 investment due to its proven profitability, strong cash flow, and continued growth potential, while acknowledging Kyverna's high-risk, high-reward profile dependent on regulatory approval of its lead candidate.